Primary Testicular DLBCL: Pathology, Diagnosis, and Comprehensive Management
Direct Recommendation
For localized (stage I-II) primary testicular DLBCL, treat with R-CHOP21 chemotherapy, mandatory CNS prophylaxis, and contralateral testis irradiation 1.
Pathology Findings
Primary testicular DLBCL demonstrates characteristic pathologic features:
Morphology: Large atypical centroblast-like neoplastic cells diffusely infiltrate testicular interstitial tissue and invade seminiferous tubules 2, 3. The cells display prominent karyokinesis, irregular nuclear membranes, scant cytoplasm, and conspicuous nucleoli 4.
Immunophenotype: Predominantly non-germinal center B-cell (non-GCB) type (82.8-84.2% of cases) by Hans classification 2, 5. Cells are positive for CD20, CD45, MUM1, and show high Ki-67 proliferation index (approximately 80%) 2, 6. The activated B-cell like (ABC) gene expression profile subtype comprises 86% of cases 5.
Invasion patterns: Tunica albuginea involvement occurs in 24.1% and vascular invasion in 17.2% of cases 2.
Diagnostic Workup
Initial Evaluation
Obtain surgical orchiectomy for definitive diagnosis - fine-needle aspirate is inadequate 7. Core biopsy should only be reserved for patients where surgical approach is impractical 7.
Required Staging Investigations
FDG-PET/CT scan: Gold standard for staging FDG-avid lymphomas 7, 8. This is critical as baseline measurement before therapy to increase accuracy of subsequent response assessment.
Laboratory tests: Complete blood count, LDH, uric acid, HIV/HBV/HCV screening, protein electrophoresis 7
Cardiac assessment: LVEF evaluation before anthracycline-based therapy 7
Bone marrow biopsy: Consider when PET-CT is negative and results would change prognosis/treatment, especially when shortened immunochemotherapy cycles are proposed 7
CNS evaluation: Diagnostic lumbar puncture should be performed in all testicular lymphoma patients given the high CNS relapse risk 7. MRI is the modality of choice for suspected CNS involvement 7.
Staging Classification
Use Ann Arbor staging system 1, 7:
- Stage I: Single lymphatic region or single extralymphatic organ (IE)
- Stage II: Two or more lymphatic regions same side of diaphragm (II) or localized extralymphatic organ with lymphatic regions same side (IIE)
- Stage III: Lymphatic regions both sides of diaphragm
- Stage IV: Diffuse/disseminated extralymphatic organ involvement
Calculate International Prognostic Index (IPI) for risk stratification 7.
Comprehensive Management by Stage
Stage I-II (Localized Disease - 87.9% of cases at presentation)
Standard treatment consists of three mandatory components 1:
R-CHOP21 chemotherapy: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone every 21 days. The number of cycles depends on age and risk factors (typically 6-8 cycles).
CNS prophylaxis: Absolutely mandatory for all testicular lymphoma 1. The optimal method remains debated - options include:
- Intrathecal methotrexate (traditional but probably suboptimal) 1
- Intravenous high-dose methotrexate (potentially superior) 1
- Combination of both approaches 1
Recent data suggests high-dose methotrexate combined with rituximab interlaced with R-CHOP may reduce CNS recurrence from 50% to 4.8% 9.
Contralateral testis irradiation: Required to prevent contralateral testicular recurrence 1
Stage III-IV (Advanced Disease)
For advanced stage disease, follow standard DLBCL treatment algorithms based on age:
Age 60-80 years: Eight cycles R-CHOP21 is standard 1. R-CHOP14 (every 14 days) shows no survival advantage over R-CHOP21 1.
Age >80 years: Comprehensive geriatric assessment required. Consider R-miniCHOP or modified regimens with doxorubicin substitution (etoposide or liposomal doxorubicin) for cardiac dysfunction 1.
Young high-risk patients (aaIPI ≥2): No established standard - clinical trial enrollment preferred. Typically 6-8 cycles R-CHOP21 1.
CNS prophylaxis remains mandatory regardless of stage 1.
Critical Management Considerations
Tumor Lysis Syndrome Prevention
In high tumor burden cases, implement precautions to avoid tumor lysis syndrome 7.
Hematopoietic Growth Factor Support
Prophylactic G-CSF is justified in patients treated with curative intent and all patients >60 years to avoid dose reductions from febrile neutropenia 7.
Avoid Dose Reductions
Maintain full chemotherapy doses whenever possible, as dose reductions compromise outcomes 7.
Response Evaluation
Interim assessment: Repeat imaging after 3-4 cycles of chemotherapy 1
End-of-treatment evaluation: PET-CT is highly recommended to define complete remission according to revised response criteria 1. Histological confirmation of PET positivity is strongly recommended if therapeutic consequences exist 1.
Bone marrow: Only repeat at end of treatment if initially involved 1
Prognosis and Patterns of Relapse
Despite early-stage presentation in most cases, primary testicular DLBCL has poor prognosis with distinctive relapse patterns 1:
- CNS relapse: Most common site (50% in CHOP era, reduced to 4.8% with R-CHOP plus CNS prophylaxis) 9
- Contralateral testis: Second most common (30% in CHOP era, reduced to 4.8% with prophylactic irradiation) 9
- Other extranodal and nodal sites: Also observed 5
Continuous risk of relapse persists even after achieving complete remission 5. Five-year survival rates: PFS 56-71%, OS 68-74% with rituximab-containing regimens 5, 9.
Rituximab significantly improves outcomes: 5-year PFS 56% vs 36% and 5-year OS 68% vs 48% compared to CHOP alone 5.
Follow-Up Protocol
- Months 0-12: History and physical examination every 3 months 1
- Months 12-36: Every 6 months 1
- After 36 months: Annually, with attention to secondary malignancies and long-term chemotherapy effects 1
Laboratory monitoring: Blood count and LDH at 3,6,12, and 24 months, then as clinically indicated 1
Imaging: CT scans at 6,12, and 24 months are usual practice, though no definitive evidence supports routine surveillance imaging in complete remission 1. Routine surveillance PET is not recommended 1.